Paul A. Stone - 16 Aug 2023 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Signature
/s/ Jason Throne, as Attorney-in-Fact for Paul A. Stone
Issuer symbol
IDYA
Transactions as of
16 Aug 2023
Net transactions value
-$106,105
Form type
4
Filing time
18 Aug 2023, 18:33:59 UTC
Previous filing
11 Aug 2023
Next filing
23 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Sale $2,645 -100 -0.52% $26.45 19,203 16 Aug 2023 Direct F1
transaction IDYA Common Stock Sale $2,640 -100 -0.52% $26.40 19,103 16 Aug 2023 Direct F1
transaction IDYA Common Stock Sale $100,820 -3,822 -20% $26.38 15,281 18 Aug 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $26.37 to $26.415, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.